Document is current
Any future updates will be listed below
-
Authors
Wang, Fen https://orcid.org/0000-0002-4876-710X
Jin, Feng
Cheng, Boran
Zhang, Yue
Zhou, Qing
Wang, Shubin
-
Clinical Trials BETA
Clinical trials referenced in this document:
isrctn35543977 at ISRCTN.orgchictr2000032265 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
https://doi.org/10.1007/s00432-021-03752-x
Documents that mention this clinical trial
The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
https://doi.org/10.1007/s00432-021-03752-x
-
Funding
Funding for this research was provided by:
Wu Jieping Medical Foundation (320.6750.19088-10)
Beijing Bethune Charitable Foundation (BQE-TY-SSPC(2)-S-01)
Sanming Project of Medicine in Shenzhen (SZSM201612041)
- License Information
-
More Information
Article History
Received: 26 February 2021
Accepted: 1 August 2021
First Online: 6 August 2021
Declarations
:
: Dr. Qing Zhou reports speaker fees from AstraZeneca and Roche. The other authors indicate no conflicts of interest.
: The study was approved by the China Ethics Committee of Registering Clinical Trials (No. ChiECRCT20200083) and performed in accordance with Good Clinical Practice and the provisions of the Declaration of Helsinki.
: Written informed consent was waived given the nature of the study.
: Informed consent was obtained from the authors.
